Beobachtungsplan, NIS 700: Tildrakizumab 200 mg for moderate to severe plaque psoriasis in routine practice in patients with elevated bodyweight or high disease burden (TIL-TWO)

Datei

• Artikel "Beobachtungsplan, NIS 700: Tildrakizumab 200 mg for moderate to severe plaque psoriasis in routine practice in patients with elevated bodyweight or high disease burden (TIL-TWO)"Herunterladen(PDF, 531KB, Datei ist nicht barrierefrei)